Max Robotics — Global Service Robot Directory + US Certification

About

Steffen Hauptmann’s research career is defined by a dedicated focus on the pathology and clinical management of borderline ovarian tumors (BOTs), a rare and diagnostically challenging gynecologic malignancy. His major contributions center on improving diagnostic accuracy and clarifying long-term patient outcomes. In his most cited work, "The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary" (2015, 14 citations), Hauptmann critically evaluated the role of this common biomarker, providing essential guidance for its use in distinguishing BOTs from invasive cancers. He further advanced the field as a key contributor to the multicenter AGO ROBOT study, a landmark pattern-of-care investigation that, through central pathology review, established robust, evidence-based standards for treatment and prognosis in a disease historically studied only in small, retrospective trials. By systematically analyzing patient outcomes across multiple centers, Hauptmann’s research has directly shaped clinical guidelines, offering clinicians clearer pathways for diagnosis and management. His work remains a foundational reference for researchers and clinicians navigating the complexities of ovarian borderline tumors.